Eikonizo Therapeutics

About:

Eikonizo Therapeutics is a biopharmaceutical company.

Description:

Eikonizo Therapeutics, Inc. was founded in October 2017 based on discoveries from Dr. Jacob Hooker’s academic lab (at MGH (Massachusetts General Hospital) and the Martinos Center for Biomedical Imaging) around novel small molecule design and human PET neuroimaging agents. ‘Eikonizo’ (ee-kuh-NEE-zo) is Greek for ‘envision’ or ‘imagine’. Eikonizo is developing life-changing therapies by creating brain penetrant and peripherally-restricted small molecules to improve the treatment of human disease.

Total Funding Amount:

$2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2017-01-01

Founders:

Frederick Schroeder, Jacob Hooker, Janice Kranz, William (Bill) Shaw

Number of Employees:

1-10

Last Funding Date:

2018-04-17

IPO Status:

Private

Industries: